阿普唑仑
外观
此條目可参照英語維基百科相應條目来扩充。 |
臨床資料 | |
---|---|
商品名 | Xanax |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684001 |
依賴性 | 高 |
给药途径 | 口服,舌下 |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 80–90% |
药物代谢 | 肝脏, 通过CYP3A4酶 |
生物半衰期 | 普释片: 11.2 小时,[1] 缓释片: 10.7–15.8 小时[2] |
排泄途徑 | 肾脏 |
识别信息 | |
| |
CAS号 | 28981-97-7 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.849 |
化学信息 | |
化学式 | C17H13ClN4 |
摩尔质量 | 308.765 |
3D模型(JSmol) | |
| |
|
阿普唑仑(Alprazolam)又名佳静安定,欧美部分国家商品名为赞安诺(Xanax)。长期服用会导致成瘾。此药在中国通常为0.4mg/片的片剂,临床一般用于抗焦虑和催眠。
与氯硝西泮的镇静作用不同,该药的药效镇静的同时又有一定改善情绪的作用,因而阿普唑仑多用于抑郁伴有失眠或焦虑的患者,而氯硝西泮多用于伴有兴奋、躁动的精神疾病患者。
副作用
可能的副作用包括:
- 失控(Disinhibition)[3]
- 性慾變化[4]
- 黄疸(非常罕見)[5]
- 幻觉(罕见)[6]
- 口乾(不频繁)[7]
- 失調、鬆弛發音[8]
- 自殺意念(罕见)[9][10]
- 尿瀦留(不频繁)[11]
- 疹、通氣不足(respiratory depression)、便秘[12][13]
- 顺行性遗忘症[14] 及注意集中等問題
- 睡意(Somnolence)、暈眩(dizziness)、頭重腳輕(lightheadedness)、疲倦、不穩定及受損的运动协调、眩暈(vertigo)[12][13]
異常反應
使用阿普唑仑有可能會發生下面的異常反應:
- 視覺變化
- 醉酒感
- 興奮
- 打电话、网络聊天
- 驾驶车辆
- 侵略[15]
- 憤怒、敵意[3]
- 震顫(Fasciculations)及手震[16]
- 瘋狂(Mania)、躁動(Psychomotor agitation)、肺熱(hyperactivity)、慌張(restlessness)[17][18][19]
食品和藥物相互作用
阿普唑崙的代謝主要是通過CYP3A4進行[20],結合CYP3A4临床上,抑製劑諸如西咪替丁、紅黴素、氟西汀、氟伏沙明、伊曲康唑、酮康唑、奈法唑酮(Nefazodone)、丙氧芬(Propoxyphene)、利托那韋(Ritonavir)等可以延緩阿普唑崙的肝清除率,但是這可能導致阿普唑崙在人体内部的的過度積纍[21],如此很有可能會導致其不良反應更加的惡化[22][23]。
參考資料
- ^ Xanax (Alprazolam) Clinical Pharmacology – Prescription Drugs and Medications. RxList. First DataBank. July 2008.
- ^ Xanax XR (Alprazolam) Clinical Pharmacology – Prescription Drugs and Medications. RxList. First DataBank. July 2008.
- ^ 3.0 3.1 Michel, L.; Lang, J. P. Benzodiazépines et passage à l'acte criminel [Benzodiazepines and Forensic Aspects]. Encephale. 2003, 29 (6): 479–485 [9 April 2013]. PMID 15029082 (法语).
- ^ ALPRAZOLAM – ORAL (Xanax) side effects, medical uses, and drug interactions. Medicinenet.com. [2 August 2007]. (原始内容存档于25 August 2007).
- ^ Noyes, R.; DuPont, R. L.; Pecknold, J. C.; Rifkin, A.; Rubin, R. T.; Swinson, R. P.; et al. Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter Trial. II. Patient Acceptance, Side Effects, and Safety. Archives of General Psychiatry. 1988, 45 (5): 423–428. PMID 3358644. doi:10.1001/archpsyc.1988.01800290037005.
- ^ Complete Alprazolam Information. Drugs.com. [2 August 2007]. (原始内容存档于5 August 2007).
- ^ Elie, R.; Lamontagne, Y. Alprazolam and Diazepam in the Treatment of Generalized Anxiety. Journal of Clinical Psychopharmacology. 1984, 4 (3): 125–129. PMID 6145726. doi:10.1097/00004714-198406000-00002.
- ^ Cassano, G. B.; Toni, C.; Petracca, A.; Deltito, J.; Benkert, O.; Curtis, G.; et al. Adverse Effects Associated with the Short-term Treatment of Panic Disorder with Imipramine, Alprazolam or Placebo. European Neuropsychopharmacology. 1994, 4 (1): 47–53. PMID 8204996. doi:10.1016/0924-977X(94)90314-X.
- ^ Hori, A. Pharmacotherapy for Personality Disorders. Psychiatry and Clinical Neurosciences. 1998, 52 (1): 13–19. PMID 9682928. doi:10.1111/j.1440-1819.1998.tb00967.x.
- ^ Kravitz, H. M.; Fawcett, J.; Newman, A. J. Alprazolam and Depression: A Review of Risks and Benefits. Journal of Clinical Psychiatry. 1993, 54 (Supplement): 78–84; discussion 85. PMID 8262892.
- ^ Alprazolam Side Effects, Interactions and Information. Drugs.com. [2 August 2007]. (原始内容存档于19 August 2007).
- ^ 12.0 12.1 Rawson, N. S.; Rawson, M. J. Acute Adverse Event Signalling Scheme Using the Saskatchewan Administrative Health Care Utilization Datafiles: Results for Two Benzodiazepines. Canadian Journal of Clinical Pharmacology. 1999, 6 (3): 159–166. PMID 10495368.
- ^ 13.0 13.1 Alprazolam – Complete Medical Information Regarding This Treatment of Anxiety Disorders. Medicinenet.com. MedicineNet. [2 August 2007].
- ^ Barbee, J. G. Memory, Benzodiazepines, and Anxiety: Integration of Theoretical and Clinical Perspectives. The Journal of Clinical Psychiatry. 1993, 54 (Suppl): 86–97; discussion 98–101. PMID 8262893.
- ^ Rapaport, M.; Braff, D. L. Alprazolam and Hostility. American Journal of Psychiatry. 1985, 142 (1): 146. PMID 2857070.
- ^ Béchir, M.; Schwegler, K.; Chenevard, R.; Binggeli, C.; Caduff, C.; Büchi, S.; et al. Anxiolytic Therapy with Alprazolam Increases Muscle Sympathetic Activity in Patients with Panic Disorders. Autonomic Neuroscience. 2007, 134 (1–2): 69–73. PMID 17363337. doi:10.1016/j.autneu.2007.01.007.
- ^ Arana, G. W.; Pearlman, C.; Shader, R. I. Alprazolam-Induced Mania: Two Clinical Cases. American Journal of Psychiatry. 1985, 142 (3): 368–369. PMID 2857534.
- ^ Strahan, A.; Rosenthal, J.; Kaswan, M.; Winston, A. Three Case Reports of Acute Paroxysmal Excitement Associated with Alprazolam Treatment. American Journal of Psychiatry. 1985, 142 (7): 859–861. PMID 2861755.
- ^ Reddy, J.; Khanna, S.; Anand, U.; Banerjee, A. Alprazolam-Induced Hypomania. Australia and New Zealand Journal of Psychiatry. 1996, 30 (4): 550–552. PMID 8887708. doi:10.3109/00048679609065031.
- ^ Otani, K. Cytochrome P450 3A4 and Benzodiazepines. Seishin Shinkeigaku Zasshi. 2003, 105 (5): 631–642. PMID 12875231 (日语).
- ^ Dresser, G. K.; Spence, J. D.; Bailey, D. G. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition. Clinical Pharmacokinetics. 2000, 38 (1): 41–57. PMID 10668858. doi:10.2165/00003088-200038010-00003.
- ^ Greenblatt, D. J.; Wright, C. E. Clinical Pharmacokinetics of Alprazolam. Therapeutic Implications. Clinical Pharmacokinetics. 1993, 24 (6): 453–471. PMID 8513649. doi:10.2165/00003088-199324060-00003.
- ^ Wang, J. S.; Chase, C. L. Pharmacokinetics and Drug Interactions of the Sedative Hypnotics (PDF). Psychopharmacological Bulletin. 2003, 37 (1): 10–29. PMID 14561946. doi:10.1007/BF01990373. (原始内容 (PDF)存档于2007-07-09).